Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Itepekimab - Regeneron Pharmaceuticals/Sanofi

Next Previous
Drug Profile

Itepekimab - Regeneron Pharmaceuticals/Sanofi

Alternative Names: REGN-3500; SAR-440340

Latest Information Update: 25 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Regeneron Pharmaceuticals; Sanofi
  • Class Anti-inflammatories; Antiasthmatics; Antibronchitics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin-33 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic obstructive pulmonary disease; Rhinosinusitis
  • Discontinued Allergic asthma; Asthma; Atopic dermatitis; Bronchiectasis

Most Recent Events

  • 20 Mar 2026 Sanofi and Regeneron Pharmaceuticals plan the phase III CEREN-4 trial for Rhinosinusitis (Monotherapy, Treatment-experienced) (SC, Injection), in May 2026 , (NCT07484230)
  • 12 Mar 2026 Phase-III clinical trials in Rhinosinusitis (Treatment-experienced) in United Kingdom (SC) (NCT07424144)
  • 20 Feb 2026 Sanofi plans a phase-III trial for Rhinosinusitis (Treatment-experienced) in March 2026 (SC), (NCT07424144)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top